Skip to main content
Top
Published in: Acta Diabetologica 5/2014

01-10-2014 | Original Article

Is early postpartum HbA1c an appropriate risk predictor after pregnancy with gestational diabetes mellitus?

Authors: Christian S. Göbl, Latife Bozkurt, Rajashri Yarragudi, Andrea Tura, Giovanni Pacini, Alexandra Kautzky-Willer

Published in: Acta Diabetologica | Issue 5/2014

Login to get access

Abstract

Compared to the 2-h oral glucose tolerance test (OGTT), the assessment of HbA1c was proposed as a less time-consuming alternative to detect pathologies in carbohydrate metabolism. This report aims to assess the predictive accuracy of HbA1c to detect alterations in glucose disposition early after gestational diabetes mellitus (GDM) pregnancy. A detailed metabolic characterization was performed in 77 women with previous GDM (pGDM) and 41 controls 3–6 month after delivery: 3-h OGTT, frequently sampled intravenous glucose tolerance test. Follow-up examinations of pGDMs were performed up to 10 years. HbA1c (venous samples, HPLC) was assessed at baseline as well as during the follow-up period (475 patient contacts). Moderate associations were observed between HbA1c and measurements of plasma glucose during the OGTT at the baseline examination: The strongest correlation was found for FPG (r = 0.40, p < 0.001), decreasing after ingestion. No associations were detected between HbA1c and OGTT dynamics of insulin or C-peptide. Moreover, baseline HbA1c showed only modest correlation with insulin sensitivity (r = −0.25, p = 0.010) and disposition index (r = −0.26, p = 0.007). A linear model including fasting as well as post-load glucose levels was not improved by HbA1c. However, pGDM females with overt diabetes manifestation during the follow-up period showed more pronounced increasing HbA1c in contrast to females remaining normal glucose tolerant or developing prediabetes. It is suggested that the performance of HbA1c assessed early after delivery is inferior to the OGTT for the detection of early alterations in glucose metabolism. However, an increase in HbA1c levels could be used as an indicator of risk for diabetes manifestation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bellamy L, Casas JP, Hingorani AD, Williams D (2009) Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta analysis. Lancet 373:1773–1779PubMedCrossRef Bellamy L, Casas JP, Hingorani AD, Williams D (2009) Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta analysis. Lancet 373:1773–1779PubMedCrossRef
2.
go back to reference International Association of Diabetes and Pregnancy Study Groups Consensus Panel (2010) International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 33:676–682CrossRefPubMedCentral International Association of Diabetes and Pregnancy Study Groups Consensus Panel (2010) International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 33:676–682CrossRefPubMedCentral
3.
go back to reference Abdul-Ghani MA, Tripathy D, DeFronzo RA (2006) Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29:1130–1139PubMedCrossRef Abdul-Ghani MA, Tripathy D, DeFronzo RA (2006) Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29:1130–1139PubMedCrossRef
4.
6.
go back to reference Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, Fowler S, Kahn SE, Diabetes Prevention Program Research Group (2008) Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrin Metab 93:4774–4779CrossRef Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, Fowler S, Kahn SE, Diabetes Prevention Program Research Group (2008) Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrin Metab 93:4774–4779CrossRef
8.
go back to reference World Health Organisation (2011) Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. World health Organisation, Geneva World Health Organisation (2011) Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. World health Organisation, Geneva
9.
go back to reference The International Expert Committee (2009) International expert committee report on the role of the A1C Assay in the diagnosis of diabetes. Diabetes Care 32:1327–1334CrossRefPubMedCentral The International Expert Committee (2009) International expert committee report on the role of the A1C Assay in the diagnosis of diabetes. Diabetes Care 32:1327–1334CrossRefPubMedCentral
10.
go back to reference Cohen RM, Haggerty S, Herman WH (2010) HbA1c for the diagnosis of diabetes and prediabetes: is it time for a mid-course correction? J Clin Endocrinol Metab 95:5203–5206PubMedCrossRefPubMedCentral Cohen RM, Haggerty S, Herman WH (2010) HbA1c for the diagnosis of diabetes and prediabetes: is it time for a mid-course correction? J Clin Endocrinol Metab 95:5203–5206PubMedCrossRefPubMedCentral
11.
go back to reference Kim C, Herman WH, Cheung NW, Gunderson EP, Richardson C (2011) Comparison of haemoglobin A1c with fasting plasma glucose and 2-h postchallenge glucose for risk stratification among women with recent gestational diabetes mellitus. Diabetes Care 34:1949–1951PubMedCrossRefPubMedCentral Kim C, Herman WH, Cheung NW, Gunderson EP, Richardson C (2011) Comparison of haemoglobin A1c with fasting plasma glucose and 2-h postchallenge glucose for risk stratification among women with recent gestational diabetes mellitus. Diabetes Care 34:1949–1951PubMedCrossRefPubMedCentral
12.
go back to reference Picon MJ, Murri M, Munoz A, Fernandez-Garcia JC, Gomez-Huelgas R, Tinahones FJ (2012) Hemoglobin A1c versus oral glucose tolerance test in postpartum screening. Diabetes Care 35:1648–1653PubMedCrossRefPubMedCentral Picon MJ, Murri M, Munoz A, Fernandez-Garcia JC, Gomez-Huelgas R, Tinahones FJ (2012) Hemoglobin A1c versus oral glucose tolerance test in postpartum screening. Diabetes Care 35:1648–1653PubMedCrossRefPubMedCentral
13.
go back to reference Winzer C, Wagner O, Festa A, Schneider B, Roden M, Bancher-Todesca D, Pacini G, Funahashi T, Kautzky-Willer A (2004) Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care 27:1721–1727PubMedCrossRef Winzer C, Wagner O, Festa A, Schneider B, Roden M, Bancher-Todesca D, Pacini G, Funahashi T, Kautzky-Willer A (2004) Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care 27:1721–1727PubMedCrossRef
14.
go back to reference Metzger BE, Coustan DR (1998) The organizing committee: summary and recommendations of the fourth international workshop-conference on gestational diabetes mellitus. Diabetes Care 21(2):161–167 Metzger BE, Coustan DR (1998) The organizing committee: summary and recommendations of the fourth international workshop-conference on gestational diabetes mellitus. Diabetes Care 21(2):161–167
15.
go back to reference Pacini G, Tonolo G, Sambataro M, Maioli M, Ciccarese M, Brocco E, Avogaro A, Nosadini R (1998) Insulin sensitivity and glucose effectiveness: minimal model analysis of regular and insulin-modified FSIGT. Am J Physiol Endocrinol Metab 274:E592–E599 Pacini G, Tonolo G, Sambataro M, Maioli M, Ciccarese M, Brocco E, Avogaro A, Nosadini R (1998) Insulin sensitivity and glucose effectiveness: minimal model analysis of regular and insulin-modified FSIGT. Am J Physiol Endocrinol Metab 274:E592–E599
16.
go back to reference Kahn SE, Prigeon RL, McCulloch DSK (2002) Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42:1663–1672CrossRef Kahn SE, Prigeon RL, McCulloch DSK (2002) Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42:1663–1672CrossRef
17.
go back to reference Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ (2001) A model based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 24:539–548PubMedCrossRef Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ (2001) A model based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 24:539–548PubMedCrossRef
18.
go back to reference Tura A, Kautzky-Willer A, Pacini G (2006) Insulinogenic indices from insulin and C-peptide:comparison of beta-cell function from OGTT and IVGTT. Diabetes Res Clin Pract 72:298–301PubMedCrossRef Tura A, Kautzky-Willer A, Pacini G (2006) Insulinogenic indices from insulin and C-peptide:comparison of beta-cell function from OGTT and IVGTT. Diabetes Res Clin Pract 72:298–301PubMedCrossRef
19.
go back to reference Göbl CS, Bozkurt L, Prikoszovich T, Winzer C, Pacini G, Kautzky-Willer A (2011) Early possible risk factors for overt diabetes after gestational diabetes mellitus. Obstet Gynecol 118:71–78PubMedCrossRef Göbl CS, Bozkurt L, Prikoszovich T, Winzer C, Pacini G, Kautzky-Willer A (2011) Early possible risk factors for overt diabetes after gestational diabetes mellitus. Obstet Gynecol 118:71–78PubMedCrossRef
20.
go back to reference Bozkurt L, Göbl CS, Tura A, Chmelik M, Prikoszovich T, Kosi L, Wagner O, Roden M, Pacini G, Gastaldelli A, Kautzky-Willer A (2012) Fatty liver index predicts further metabolic deteriorations in women with previous gestational diabetes. PLoS ONE 7:e32710PubMedCrossRefPubMedCentral Bozkurt L, Göbl CS, Tura A, Chmelik M, Prikoszovich T, Kosi L, Wagner O, Roden M, Pacini G, Gastaldelli A, Kautzky-Willer A (2012) Fatty liver index predicts further metabolic deteriorations in women with previous gestational diabetes. PLoS ONE 7:e32710PubMedCrossRefPubMedCentral
21.
go back to reference Tura A, Grassi A, Winhofer Y, Guolo A, Pacini G, Mari A, Kautzky-Willer A (2012) Progression to type 2 diabetes in women with former gestational diabetes: time trajectories of metabolic parameters. PLoS ONE 7:e50419PubMedCrossRefPubMedCentral Tura A, Grassi A, Winhofer Y, Guolo A, Pacini G, Mari A, Kautzky-Willer A (2012) Progression to type 2 diabetes in women with former gestational diabetes: time trajectories of metabolic parameters. PLoS ONE 7:e50419PubMedCrossRefPubMedCentral
22.
go back to reference Göbl CS, Bozkurt L, Prikoszovich T, Tura A, Pacini G, Kautzky-Willer A (2013) Estimating the risk after gestational diabetes mellitus: can we improve the information of the postpartum OGTT? Am J Physiol Endocrinol Metab 304:E524–E530PubMedCrossRef Göbl CS, Bozkurt L, Prikoszovich T, Tura A, Pacini G, Kautzky-Willer A (2013) Estimating the risk after gestational diabetes mellitus: can we improve the information of the postpartum OGTT? Am J Physiol Endocrinol Metab 304:E524–E530PubMedCrossRef
23.
go back to reference Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Müller M (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform 7:77. doi:10.1186/1471-2105-12-77 CrossRef Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Müller M (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform 7:77. doi:10.​1186/​1471-2105-12-77 CrossRef
25.
go back to reference Lorenzo C, Wagenknecht LE, Hanley AJ, Rewers MJ, Karter AJ, Haffner SM (2010) A1C between 5.7 and 6.4 % as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance and Atherosclerosis Study (IRAS). Diabetes Care 33:2104–2109PubMedCrossRefPubMedCentral Lorenzo C, Wagenknecht LE, Hanley AJ, Rewers MJ, Karter AJ, Haffner SM (2010) A1C between 5.7 and 6.4 % as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance and Atherosclerosis Study (IRAS). Diabetes Care 33:2104–2109PubMedCrossRefPubMedCentral
26.
go back to reference Kanat M, Winnier D, Norton L, Arar N, Jenkinson C, DeFronzo RA, Abdul-Ghani MA (2011) The relationship between β-cell function and glycated hemoglobin: results from the veterans administration genetic epidemiology study. Diabetes Care 34:1006–1010PubMedCrossRefPubMedCentral Kanat M, Winnier D, Norton L, Arar N, Jenkinson C, DeFronzo RA, Abdul-Ghani MA (2011) The relationship between β-cell function and glycated hemoglobin: results from the veterans administration genetic epidemiology study. Diabetes Care 34:1006–1010PubMedCrossRefPubMedCentral
27.
go back to reference Bianchi C, Miccoli R, Bonadonna RC, Giorgino F, Frontoni S, Faloia E, Marchesini G, Dolci MA, Cavalot F, Cavallo GM, Leonetti F, Del Prato S, GENFIEV Investigators (2012) Pathogenetic mechanisms and cardiovascular risk: differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance. Diabetes Care 35:2607–2612PubMedCrossRefPubMedCentral Bianchi C, Miccoli R, Bonadonna RC, Giorgino F, Frontoni S, Faloia E, Marchesini G, Dolci MA, Cavalot F, Cavallo GM, Leonetti F, Del Prato S, GENFIEV Investigators (2012) Pathogenetic mechanisms and cardiovascular risk: differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance. Diabetes Care 35:2607–2612PubMedCrossRefPubMedCentral
28.
go back to reference Ahrén B, Pacini G (2004) Importance of quantifying insulin secretion in relation to insulin sensitivity to accurate assess beta cell function in clinical studies. Eur J Endocrinol 150:97–104PubMedCrossRef Ahrén B, Pacini G (2004) Importance of quantifying insulin secretion in relation to insulin sensitivity to accurate assess beta cell function in clinical studies. Eur J Endocrinol 150:97–104PubMedCrossRef
29.
go back to reference Kautzky-Willer A, Handisurya A (2009) Metabolic diseases and associated complications: sex and gender matter! Eur J Clin Invest 39:631–648PubMedCrossRef Kautzky-Willer A, Handisurya A (2009) Metabolic diseases and associated complications: sex and gender matter! Eur J Clin Invest 39:631–648PubMedCrossRef
30.
go back to reference Morris DH, Khunti K, Achana F, Srinivasan B, Gray LJ, Davies MJ, Webb D (2013) Progression rates from HbA1c 6.0–6.4% and other prediabetes definitions to type 2 diabetes: a meta analysis. Diabetologia 56:1489–1493PubMedCrossRef Morris DH, Khunti K, Achana F, Srinivasan B, Gray LJ, Davies MJ, Webb D (2013) Progression rates from HbA1c 6.0–6.4% and other prediabetes definitions to type 2 diabetes: a meta analysis. Diabetologia 56:1489–1493PubMedCrossRef
31.
go back to reference Mann DM, Carson AP, Shimbo D, Fonseca V, Fox CS, Mutner P (2010) Impact of A1C screening criterion on the diagnosis of pre-diabetes among U.S. adults. Diabetes Care 33:2190–2195PubMedCrossRefPubMedCentral Mann DM, Carson AP, Shimbo D, Fonseca V, Fox CS, Mutner P (2010) Impact of A1C screening criterion on the diagnosis of pre-diabetes among U.S. adults. Diabetes Care 33:2190–2195PubMedCrossRefPubMedCentral
32.
go back to reference James C, Bullard KM, Rolka DB, Geiss LS, Williams DE, Cowie CC, Albright A, Gregg EW (2011) Implications of alternative definitions of prediabetes for prevalence in U.S. adults. Diabetes Care 34:387–391PubMedCrossRefPubMedCentral James C, Bullard KM, Rolka DB, Geiss LS, Williams DE, Cowie CC, Albright A, Gregg EW (2011) Implications of alternative definitions of prediabetes for prevalence in U.S. adults. Diabetes Care 34:387–391PubMedCrossRefPubMedCentral
33.
go back to reference Lapolla A, Mosca A, Fedele D (2011) The general use of glycated haemoglobin for the diagnosis of diabetes and other categories of glucose intolerance: still a long way to go. Nutr Metab Cardiovasc Dis 21:467–475PubMedCrossRef Lapolla A, Mosca A, Fedele D (2011) The general use of glycated haemoglobin for the diagnosis of diabetes and other categories of glucose intolerance: still a long way to go. Nutr Metab Cardiovasc Dis 21:467–475PubMedCrossRef
34.
go back to reference Seals DR, Hagberg JM, Allen WK, Hurley BF, Dalsky GP, Ehsani AA, Holloszy JO (1984) Glucose tolerance in young and older athletes and sedentary men. J Appl Physiol 56:1521–1525PubMed Seals DR, Hagberg JM, Allen WK, Hurley BF, Dalsky GP, Ehsani AA, Holloszy JO (1984) Glucose tolerance in young and older athletes and sedentary men. J Appl Physiol 56:1521–1525PubMed
35.
go back to reference Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, Lachin JM, Montez MG, Brenneman T, Barrett-Connor E (2007) Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the diabetes prevention program. Diabetes Care 30:2453–2457PubMedCrossRefPubMedCentral Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, Lachin JM, Montez MG, Brenneman T, Barrett-Connor E (2007) Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the diabetes prevention program. Diabetes Care 30:2453–2457PubMedCrossRefPubMedCentral
36.
go back to reference Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, Bouatia-Naji N, Langenberg C, Prokopenko I, Stolerman E, Sandhu MS, Heeney MM, Devaney JM, Reilly MP, Ricketts SL (2010) Common variants at ten genomic loci influence haemoglobin A1C levels via glycemic and non-glycemic pathways. Diabetes 59:3229–3239PubMedCrossRefPubMedCentral Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, Bouatia-Naji N, Langenberg C, Prokopenko I, Stolerman E, Sandhu MS, Heeney MM, Devaney JM, Reilly MP, Ricketts SL (2010) Common variants at ten genomic loci influence haemoglobin A1C levels via glycemic and non-glycemic pathways. Diabetes 59:3229–3239PubMedCrossRefPubMedCentral
37.
go back to reference Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, Ciraolo PJ, Palascak MB, Joiner CH (2008) Red cell lifespan heterogeneity in haematologically normal people is sufficient to alter HbA1c. Blood 112:4284–4291PubMedCrossRefPubMedCentral Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, Ciraolo PJ, Palascak MB, Joiner CH (2008) Red cell lifespan heterogeneity in haematologically normal people is sufficient to alter HbA1c. Blood 112:4284–4291PubMedCrossRefPubMedCentral
38.
go back to reference Hardikar PS, Joshi SM, Bhat DS, Raut DA, Katre PA, Lubree HG, Jere A, Pandit AN, Fall CHD, Yajnik CS (2012) Spuriously high prevalence of prediabetes diagnosed by HbA1c in young Indian partly explained by haematological factors and iron deficiency anemia. Diabetes Care 35:797–802PubMedCrossRefPubMedCentral Hardikar PS, Joshi SM, Bhat DS, Raut DA, Katre PA, Lubree HG, Jere A, Pandit AN, Fall CHD, Yajnik CS (2012) Spuriously high prevalence of prediabetes diagnosed by HbA1c in young Indian partly explained by haematological factors and iron deficiency anemia. Diabetes Care 35:797–802PubMedCrossRefPubMedCentral
39.
go back to reference Kim C, Bullard KM, Herman WH, Berckles GL (2010) Association between iron deficiency and A1C levels among adults without diabetes in the National Health and Nutrition Survey, 1999–2006. Diabetes Care 33:780–785PubMedCrossRefPubMedCentral Kim C, Bullard KM, Herman WH, Berckles GL (2010) Association between iron deficiency and A1C levels among adults without diabetes in the National Health and Nutrition Survey, 1999–2006. Diabetes Care 33:780–785PubMedCrossRefPubMedCentral
Metadata
Title
Is early postpartum HbA1c an appropriate risk predictor after pregnancy with gestational diabetes mellitus?
Authors
Christian S. Göbl
Latife Bozkurt
Rajashri Yarragudi
Andrea Tura
Giovanni Pacini
Alexandra Kautzky-Willer
Publication date
01-10-2014
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 5/2014
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-014-0574-2

Other articles of this Issue 5/2014

Acta Diabetologica 5/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.